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Abstract
Aims Since the introduction of transcatheter aortic valve im-
plantation (TAVI), newer generation and novel devices such
as the retrievable JenaValve™ have been developed. We
evaluated the procedural and 6-month results of our first
experience with implantation of the JenaValve™.
Methods and results From June 2012 to December 2013, 24
consecutive patients (mean age 80±7 years, 42 % male)
underwent an elective transapical TAVI with the JenaValve™.
Device success was 88 %. The mortality rate was 4 % at
30 days and 31 % at 6 months. TAVI reduced the mean
transvalvular gradient (44.2±11.1 mmHg vs. 12.3±
4.3 mmHg, p<0.001) and increased the mean aortic valve
area (0.8 3±0.23 to 1.70±0.44 cm2). A mild paravalvular
leakage (PVL) occurred in 4 patients (18 %) and a moderate
PVL in 1 patient (4 %). Mean New York Heart Association
Functional Class improved from 2.9±0.5 to 2.0±0.8 at
30 days.
Conclusion TAVI using the JenaValve™ prosthesis seems
adequate and safe in this first experience cohort.
Keywords Aortic stenosis . Transcatheter aortic valve
implantation . Transapical . TAVI . Jenavalve . PVL .
Complication
Introduction
Currently, transcatheter aortic valve implantation (TAVI) is
routine therapy in inoperable or high-risk patients with severe
aortic stenosis [1, 2]. Two prostheses are predominantly used
in clinical practice: the balloon-expandable SAPIEN XT™
bioprosthesis (Edwards Lifesciences, Irvine, USA), and the
self-expandable CoreValve™ bioprosthesis (Medtronic, Min-
neapolis, USA). Newer developments focus on overcoming
certain drawbacks of the SAPIEN XT™ and CoreValve™
prostheses, such as the limited capability of positioning and
repositioning, retrieval, and the relatively high rate of
periprosthetic paravalvular leakage (PVL). One such novel
device is the JenaValve™ (JenaValve Technology GmbH,
Munich), which received its CE approval for aortic stenosis
in September 2011 and aortic regurgitation in September
2013. In this paper, we present the results of our first experi-
ence with implantation of the JenaValve™ for aortic stenosis.
Methods
Definitions
Endpoints were defined according to the updated Valve Aca-
demic Research Consortium (VARC)-2 [3] Consensus Docu-
ment. The severity of PVL was determined by colour Doppler
using transthoracic and transoesophageal echocardiography.
The degree of PVL was classified as: 0 (none or trace), I
(mild), II (moderate), or III (severe). Operative risk was de-
termined with the Logistic EuroSCORE, EuroSCORE II, and
the Society of Thoracic Surgeons (STS) score.
Bleeding complications were classified according to the
consensus report from the Bleeding Academic Research Con-
sortium (BARC) [4]. Acute kidney injury was classified using
the Acute Kidney Injury Network (AKIN) classification
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system [5]. Early safety was defined as freedom of all-cause
mortality, stroke, life-threatening bleeding, acute kidney inju-
ry (AKIN class II or III including renal replacement therapy),
coronary artery obstruction requiring intervention, major vas-
cular complication as defined by VARC-2 [3], and device-
related valvular dysfunction requiring repeat procedure. Early
safety was measured at 30 days. Procedure-related death was
defined as all-cause mortality ≤30 days or during index
hospitalisation if >30 days. Device success was defined as
freedom of procedure mortality, correct positioning of the
closure device, and the intended performance of the closure
device.
Patient population
From June 2012 to December 2013, we included all patients
who underwent a TAVI using a JenaValve™ prosthesis
(Fig. 1) in our institution. Patients were not eligible for
transfemoral TAVI because of peripheral artery disease. All
patients were discussed in a dedicated heart team consisting of
at least one cardiothoracic surgeon, interventional cardiolo-
gist, and imaging specialist. Patients were considered ineligi-
ble for surgery because of a too high procedural risk, and were
informed about the considerations and risks prior to
intervention.
Procedure
All procedures were performed under general anaesthesia in a
specialised fully equipped hybrid catheterisation laboratory.
Prophylactic antibiotics were given prior to the procedure. A
temporary pacemaker lead was positioned transjugular in the
right ventricle and tested at 180 bpm.
The common femoral artery was punctured using the
standard technique. After administration of 5000 IU of
unfractionated heparin with an activated clotting time
≥250 s, a pigtail catheter was advanced through a 5-
French sheath into the ascending aorta for haemodynamic
measurements and angiographic control. The optimal an-
gulation of the fluoroscopic system was selected in con-
cordance with pre-procedural computed tomographic (CT)
imaging measurements. The fluoroscopic plane was per-
pendicular to the aortic annulus, whereby all three aortic
valve leaflets were aligned and the course of the coronary
arteries was identified.
The cardiac apex was exposed using a small left an-
terolateral thoracotomy between the fifth and sixth rib by
a cardiothoracic surgeon, allowing direct visualisation for
opening the pericardium. Purse string sutures with 2×4
pledgets were applied. The left ventricle was then punc-
tured and a 14-French sheath was advanced into the left
ventricular cavity using Seldinger’s technique. A J-curved
stiff guide wire was advanced through the native aortic
valve into the descending aorta. A straight valvuloplasty
balloon was advanced over the wire and positioned within
the stenotic aortic valve. Balloon diameter was chosen to
be 2–5 mm smaller than the native aortic annulus mea-
sured by transoesophageal echocardiography. To predilate
the stenotic aortic valve, standard apical aortic
valvuloplasty was performed during rapid right ventricu-
lar pacing at 180–220 bpm.
After pre-dilatation, the 14-French sheath was exchanged
for the 32-French delivery sheath through which the
JenaValve™ prosthesis was carefully advanced into the native
aortic valve (Fig. 2a). The prosthesis was sized according to
the annular perimeter on CT: a 23 mm valve for a perimeter of
≤72mm, a 25 mm valve for a perimeter of 72 to 78.5 mm, and
a 27 mm valve for a perimeter ≥78.5 mm. Once the distal
catheter was in a supra-valvular position, we opened the
sheath releasing the three ‘positioning feelers’. Subsequently,
the catheter was carefully retracted, bringing each arm in the
corresponding aortic sinus (Fig. 2b). This manoeuvre was
performed under careful fluoroscopic guidance, verifying the
correct position by the conjoint movement of each free arm in
synchrony with each heartbeat. The device was released by
careful unsheathing (Fig. 2c and d).
Fluoroscopic imaging and transoesophageal echocardiog-
raphy were used to assess haemodynamic function and posi-
tioning of the valve in relation to the anatomic landmarks. An
invasive transaortic pressure gradient was measured. In case
of a high aortic peak gradient or a moderate to severe PVL,
post-dilatation was performed. After retraction of the delivery
system, haemostasis was secured by the purse-string sutures.
When good haemostasis was achieved, a thoracic drain was
placed. After standard wound closure, the patient was
extubated and transferred to the post-anaesthetic care unit.
Fig. 1 JenaValve™ prosthesis. Source: JenaValve Technology GmbH,
Munich
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Follow-up
Before discharge, a transthoracic echocardiography was rou-
tinely performed. Follow-up was performed at one and six
months post-procedure.
Data analysis
Data are presented as mean ± standard deviation or as median
with interquartile range (IQR) as appropriate. Categorical
variables are shown as frequencies and percentages. For pre-
post comparison we used the paired sample T-test or the
Wilcoxon signed-rank test as appropriate. Statistical signifi-
cance was inferred at p<0.05.
Results
Patient characteristics
Twenty-four patients (mean age 80±7 years, 42 % male)
underwent a transapical TAVI using the JenaValve™ prosthe-
sis in our centre. All patients suffered from severe symptom-
atic aortic stenosis. NYHA functional class was ≥ II in all
patients: class II in four patients (17 %), class III in 18 patients
(75 %), and class IV in two patients (8 %). Impaired left
ventricular ejection fraction (LVEF) was present in four pa-
tients (17 %). Mean logistic EuroSCORE was 25±12 %,
EuroSCORE II 5±5 %, and STS score 5±3 %. Demographic
and baseline characteristics are listed in Table 1.
Procedure
A JenaValve™ prosthesis was successfully implanted in 21
patients (88 %). Of the unsuccessful procedures, one patient
died due to an unknown cause at day 17, one patient had a
moderate residual PVL, and one patient had an aortic mean
gradient >20 mmHg. Procedural results are listed in Table 2.
Post-dilatation was used in 16 patients (67 %). We encoun-
tered no cases of valve malpositioning, unplanned cardiopul-
monary bypass was not used, and there was no need for
further interventions such as TAVI-in-TAVI or conversion to
open surgery.
Safety
Thirty-daymortality was 4% (95%CI 1 to 20%) (N=1). This
patient died of an unknown cause. The composite safety
endpoint was met in 21 patients (88 %, 95 % CI 70 to
96 %). Three patients did not meet this endpoint. Besides
one death, an ischaemic stroke occurred in one patient (4 %)
at day 0 complicated with a right-sided hemiparesis and
dysarthria. This patient received aspirin and was loaded with
clopidogrel (300 mg) the day before TAVI. Acute Kidney
Injury Network (AKIN) class II occurred in 1 patient (4 %)
(raise of creatinine from 98 to 278 μmol/L) due to forward
failure and dehydration. Creatinine improved compared with
before the procedure in 12 (50 %) patients.
Peri-procedure, a non-ST-elevation myocardial infarction
occurred in 1 patient (4 %) at day 0. A post-procedural
delirium occurred in three patients (13 %). During
hospitalisation, a new left bundle branch block (LBBB) oc-
curred in nine patients (38 %) and a pacemaker was implanted
Fig. 2 Stepwise implantation of the JenaValve™ prosthesis. Inferior images adapted with permission from JenaValve Technology GmbH, Munich
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in three patients (13 %). Regarding bleeding, no life-
threatening bleeding occurred. Major bleeding occurred in
one patient (4 %) with diverticulitis who developed major
gastrointestinal bleeding which required two blood transfu-
sions. Minor bleeding occurred in three (13 %) patients and
consisted of a femoral arterial bleed, gastrointestinal bleeding
in a patient with ulcerative colitis, and a small transapical
bleed observed in the thoracic drain. A major vascular access
site-related complication occurred in one patient (4 %) who
developed a false aneurysm of the femoral artery. Two patients
(8 %) who had no complications were discharged without
antiplatelet therapy. Complications are listed in Table 3.
Functional
The mean NYHA functional class improved from 2.9±0.5 to
2.0±0.8 at 30 days (P<0.001). Transvalvular pressure gradi-
ents significantly decreased by approximately 40 mmHg aor-
tic peak gradient and 30 mmHg aortic mean gradient
(P<0.001). The mean aortic valve area increased from 0.83
±0.23 to 1.70±0.44 cm2 (P<0.000). A mild PVL occurred in
4 patients (18 %) and a moderate PVL in 1 patient (4 %). The
mean LVEF remained stable. Echocardiographic parameters
are displayed in Table 4 and Fig. 3.
Follow-up
Patients were discharged from hospital after a median of
7 days (IQR 5 days). Median stay in intensive care was
1 day (IQR 1 day). Median follow-up was four (IQR 12)
months. Six-month follow-up was completed for 16 pa-
tients (67 %).
At 6-month follow-up, five patients had died (31 %). Three
patients died of a non-cardiovascular cause. Of these, one
patient died due to sepsis with S. epidermidis without evi-
dence of endocarditis at day 46, 1 due to renal failure at day
57, and one patient due to a community-acquired pneumonia
at day 67. Of the cardiovascular causes, one patient died at
home due to an unknown cause at day 99, and one patient due
to decompensated right-sided cardiac failure with impaired
liver function at day 57.
Table 2 Procedural characteristics






Conversion to open surgery (0) 0
Valve-in-valve (0) 0
Coronary ostium occlusion (0) 0
Vascular complication
False aneurysm (1) 4
Composites
Device success (21) 88
Early safety (21) 88
Categorical values are n (%)
Table 1 Baseline characteristics (n=24)




Logistic EuroSCORE (%) 25±12
EuroSCORE II (%) 5±5
















Diabetes mellitus (7) 29
CKI (2) 8
Atrial fibrillation (7) 29








BMI, Body mass index; CABG, coronary artery bypass graft; CAD,
coronary artery disease; CKI, chronic kidney injury; COPD, chronic
obstructive pulmonary disease; LVEF, left ventricular ejection fraction;
NYHA, New York Heart Association; PAD, peripheral artery disease;
PHT, pulmonary hypertension; STS, Society of Thoracic Surgeons
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Discussion
The available TAVI prostheses evolve rapidly, and various
self-expanding, balloon-inflatable, and self-inflatable devices
exist. In this paper, we describe our experiences with the
JenaValve™ (JenaValve Technology GmbH, Munich), which
received its CE approval for aortic stenosis in September 2011
and for aortic regurgitation in September 2013.
The JenaValve™ is a second-generation self-expandable
device composed of a trileaflet porcine root valve mounted on
nitinol double bowed struts with three positioning feelers. It is
available in three sizes (23, 25, and 27 mm) in Europe,
covering an aortic annulus range of 21–27 mm. This prosthe-
sis can currently only be implanted by an anterograde ap-
proach, although a clinical trial for transfemoral delivery starts
this year. The three positioning feelers give the JenaValve™
its capability to guide an exact positioning with the possibility
of repositioning. Its method of anchoring, namely clamping
itself around the native cusps, is very different from the radial
force onto the aortic annulus and/or descending aorta used in
for example the SAPIEN XT™ and CoreValve™ prostheses
(Table 5).
The procedure success in our cohort was 88% (N=21). This
is comparable with the procedure success in the JenaValve™
CE-mark approval study: 82 % (seven conversions of proce-
dure, five deaths). However, we experienced no cases of device
malpositioning, conversion to surgery, conversion valve-in-
valve, or conversion to another TAVI device. The positioning
of the device could be performed in a very well-controlled
manner and the ‘Cathlete plus’ delivery system allowed a
step-by-step and controllable opening of the device.
The ‘real-world’ 30-day mortality rate after TAVI is ap-
proximately 7.5 to 8 %. [6–8] In transapical procedures, the
mortality rate is generally higher compared with transarterial
procedures (approximately 10–11 vs. 5–6 %) [7, 8]. These
differences in mortality rate could partially be explained by
the fact that transapical TAVI is usually performed on higher
risk patients and that comorbidities interact differently per
approach. Also, experience with the approach is related to
mortality [9], and outcome improves with experience [10].
The CE-mark approval study for the JenaValve™ found a
mortality rate of 7.6 % at 30 days (7 of 66 patients) [11]. In
our cohort, 30-day mortality was 4 % (N=1). This seems
favourably low, although it could be partially explained by
the small sample size. However, also the rate of the VARC
defined safety endpoint (i.e. event-free survival) at 30 days
was high (88 %, N=21). This is comparable with the rate of
Table 3 Echocardiographic parameters
Baseline (n=23) Discharge (n=22) 30 Days (n=18) p
LVEF 59±15 59±10 59±14 0.78
Maximal aortic velocity 407±70 259±55 256±45 <0.01
Maximal aortic PG 70±22 28±12 27±10 <0.01
Mean aortic PG 42±14 14±6 14±5 <0.01
AVA 0.83±0.23 1.79±0.59 1.70±0.44 <0.01
Aortic regurgitation 0.13
Valvular AR (mild) (5) 22 (0) 0 (0) 0
Paravalvular AR (mild) (0) 0 (4) 18 (3) 17
Paravalvular AR (moderate) (0) 0 (1) 4 (1) 6
PASP 34±16 37±14 33±11 0.50
Categorical values are n (%). P values signify paired test between baseline and discharge. AR, aortic regurgitation; AVA, aortic valve area; LVEF, left
ventricular ejection fraction; PG, peak gradient; PASP, pulmonary artery systolic pressure
Table 4 Major complications
30 days (n=24) 6 months (n=16)
Death
All-cause death (1) 4 (5) 31
Cardiovascular death (1) 4 (2) 13
Stroke (1) 4 (1) 6
Myocardial infarction (1) 4 (1) 6
Acute kidney injury
AKIN I (2) 8 –
AKIN II (1) 4 –
Bleeding
Major (1) 4 (1) 6
Minor (3) 13 (3) 19
New AF (2) 8 –
New LBBB (9) 38 –
New pacemaker (3) 13 (4) 25
Major complications at mean follow-up (168±30 days). Categorical
values are n (%). AF, atrial fibrillation; AKIN, acute kidney injury net-
work; LBBB, left bundle branch block
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safety endpoint after transfemoral TAVI [12]. The rate of PVL
in our cohort also seemed promising, with only one case of
moderate PVL (4 %). In the CE-mark approval study, PVL
was seen in 53 % of patients (all mild or moderate). The low
severity of PVL is encouraging, since not only moderate to
severe but even mild PVL may impact mortality [13, 14].
One procedural disabling stroke occurred in a patient with
severe extensive aortic calcification on dual antiplatelet ther-
apy. Despite the availability of a protocol for antithrombotic
therapy at our centre, the treatment regimen differed on dis-
charge: not all patients received antiplatelet therapy [15]. This
strategy is used by more centres, and seemed to have no
negative implication in this population.
Conduction disturbances after TAVI are frequent and highly
device dependent, with a five times higher incidence of new
permanent pacemaker implantation after CoreValve™ com-
pared with SAPIEN XT™ [7]. The rate of pacemaker implan-
tation after TAVI was 13 % (N=3) in our cohort, comparable to
the CE-mark approval trial [11]. The observed lower rate com-
pared with the CoreValve™ might be explained by the lower
stent profile and its different method of anchoring, resulting in a
reduced implantation depth in the left ventricular outflow tract
and reduced radial forces at the level of the annulus and its
surrounding tissue. However, the occurrence of newLBBBwas
seen in 38 % of cases in this series. This is of importance, since
LBBB has been shown to be an independent and important risk
factor for all-cause mortality after TAVI at 16 months [16]. No
total incidence of new LBBB was documented in the CE-mark
trial for the JenaValve™ [11] and future studies should address
the rate and consequences of LBBB after implantation of the
JenaValve™.
In our first experience, we find JenaValve™ an ade-
quate prosthesis with a high success in implantation,
also in less severely calcified aortic annuli. Since the
JenaValve™ in fact grabs the native leaflets, this pros-
thesis might be indicated in non-calcified native valves
such as in severe aortic regurgitation [17]. This is in
contrast to the SAPIEN XT™ valve, which is anchored
purely by radial force and needs some kind of calcifi-
cation to plant itself and reduce the risk of valve em-
bolisation and aortic annular rupture (Table 6). It seems
that with novel devices like the JenaValve™, a more
tailored approach to device selection with regard to
anatomical factors could be applied.
Conclusion
In conclusion, transapical transcatheter implantation using the
second-generation JenaValve™ prosthesis seemed adequate
Fig. 3 Echocardiographic
assessment at baseline, discharge
and 30 days of follow-up for
mean aortic peak gradient (PG)
and aortic valve area (AVA)
Table 5 Differences in prosthesis characteristics
CoreValve™ SAPIEN XT™ JenaValve™
Valve tissue Porcine
pericardium
Bovine pericardium Porcine root
Stent Nitinol frame Cobalt chromium
alloy
Nitinol frame
Valve location Supra-annular Intra-annular Intra-annular
Implantation Self expanding Balloon expandable Self-expanding





18 French 16 and 18 French 32 French
Differences between the CoreValve™, SAPIEN XT™, and JenaValve™
prosthesis
Table 6 Suggested indications for SAPIEN XT and JenaValve in
transapical approach
SAPIEN XT™ JenaValve™
Aortic annulus range 18–27 21–27
Straight ascending aorta ≥65 mm
Distance between annulus and
coronary ostia
≥10 mm ≥8 mm
Bicuspid aortic valve ++ –
Degenerated prosthesis ++ –
Porcelain aorta ++ -
Severe calcified nodules on native leaflet + +/−
Non-calcified aortic valve (e.g. AR) - +++
Small distance annulus to coronary ostia +/− ++
With the development of novel TAVI devices, a more tailored approach to
device selection with regard to anatomical factors could be applied
40 Neth Heart J (2015) 23:35–41
and safe in this first experience cohort. An advantage of this
device is its precise anatomical positioning. Overall, the sec-
ond generation JenaValve™ device offers a novel treatment
option for TAVI.
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